Okyanos Heart Institute Chief Medical Officer Presents to Transcatheter Cardiovascular Therapeutics Meeting
Dr. Howard T. Walpole Jr. Will Speak at Educational Meeting Specializing in Interventional Cardiovascular Medicine Oct. 23
Freeport, Bahamas, The, October 05, 2012 --(PR.com)-- Matt Feshbach, CEO of Okyanos Heart Institute (http://www.okyanos.com/), which brings a new standard of care and a better quality of life to patients with coronary artery disease (CAD) using cardiac cell therapy, has announced that Chief Medical Officer Howard T. Walpole Jr., M.D., MBA, FACC, FACAI, FSCAI, will present to the 2012 Transcatheter Cardiovascular Therapeutics (TCT) meeting on Tuesday, Oct. 23. TCT, the world’s largest educational meeting focusing on interventional cardiovascular medicine, showcases the latest advances in current therapies and clinical research. Dr. Walpole will give two presentations: “The Cardiovascular (CV) Service Line: Patients, Products and Referrals” and “The Physician Executive: Do I Need an MBA or Not?” During the meeting, attendees will learn ways to better understand results from important clinical trials and evidence-based medicine, as well as identify new interventional technologies and appropriate applications for patients with cardiovascular disease.
Quotes:
“Dr. Walpole has extensive expertise as a cardiologist and key opinion leader in the cardiology community, and we look forward to him sharing some of his knowledge at the 2012 Transcatheter Cardiovascular Therapeutics meeting,” said Feshbach. “His presentations will provide attendees with crucial updates on our field’s most pressing and relevant issues as part of our commitment to advancing treatment methods for cardiovascular patients.”
“To be asked to present at the 2012 Transcatheter Cardiovascular Therapeutics meeting is an incredible opportunity, and I am excited to be a part of such an internationally recognized event as well as have the chance to learn from other presenters,” said Walpole. “As the chief medical officer for Okyanos Heart Institute, I am dedicated to expanding my knowledge base to better serve the staff and patients at our institute and the cardiology community at large.”
Details:
For more information about TCT, visit http://www.tctconference.com/about-tct/overview.html.
New Media Content:
Okyanos Blog:
http://bit.ly/Prsdux
Okyanos LinkedIn page:
http://linkd.in/Prsgqd
Okyanos Facebook page:
http://on.fb.me/TKiXTi
Okyanos Twitter page:
http://bit.ly/OFZPqk
About Okyanos Heart Institute:
Based in Freeport, the Bahamas, the Okyanos Heart Institute is a Center of Excellence (CoE) adhering to U.S. surgical center standards and led by Chief Medical Officer Howard T. Walpole Jr., M.D., MBA, FACC, FACAI, FSCAI, a leader of the American College of Cardiology for many years. The mission of Okyanos Heart Institute is to bring a new standard of care and a better quality of life to patients with chronic coronary artery disease using cardiac cell therapy. The Okyanos treatment utilizes cardiac cell therapy, a unique blend of stem and regenerative cells to support the growth of new blood vessels and to assist the heart in repairing tissue damaged by heart attack and disease. The Greek god of rivers, “Okyanos” symbolizes the primary mechanism of action that these adult stem cells have on ischemic (lack of blood flow) heart tissue, the result of the plaque deposits in the coronary arteries. The stem cells, derived from a person’s adipose (fat) tissue, create new blood vessels, a process known as angiogenesis. These cells facilitate blood flow in the heart and intake and use of oxygen, as measured by a rigorous clinical trial known as the PRECISE trial, as well as cardiac cell therapy trials at leading research institutions. For more information, visit http://www.okyanos.com/.
Anjelica Cummings
MMI Public Relations
(919) 233-6600
anjelica@mmipublicrelations.com
http://twitter.com/MMIPR
http://www.mmipublicrelations.com
Quotes:
“Dr. Walpole has extensive expertise as a cardiologist and key opinion leader in the cardiology community, and we look forward to him sharing some of his knowledge at the 2012 Transcatheter Cardiovascular Therapeutics meeting,” said Feshbach. “His presentations will provide attendees with crucial updates on our field’s most pressing and relevant issues as part of our commitment to advancing treatment methods for cardiovascular patients.”
“To be asked to present at the 2012 Transcatheter Cardiovascular Therapeutics meeting is an incredible opportunity, and I am excited to be a part of such an internationally recognized event as well as have the chance to learn from other presenters,” said Walpole. “As the chief medical officer for Okyanos Heart Institute, I am dedicated to expanding my knowledge base to better serve the staff and patients at our institute and the cardiology community at large.”
Details:
For more information about TCT, visit http://www.tctconference.com/about-tct/overview.html.
New Media Content:
Okyanos Blog:
http://bit.ly/Prsdux
Okyanos LinkedIn page:
http://linkd.in/Prsgqd
Okyanos Facebook page:
http://on.fb.me/TKiXTi
Okyanos Twitter page:
http://bit.ly/OFZPqk
About Okyanos Heart Institute:
Based in Freeport, the Bahamas, the Okyanos Heart Institute is a Center of Excellence (CoE) adhering to U.S. surgical center standards and led by Chief Medical Officer Howard T. Walpole Jr., M.D., MBA, FACC, FACAI, FSCAI, a leader of the American College of Cardiology for many years. The mission of Okyanos Heart Institute is to bring a new standard of care and a better quality of life to patients with chronic coronary artery disease using cardiac cell therapy. The Okyanos treatment utilizes cardiac cell therapy, a unique blend of stem and regenerative cells to support the growth of new blood vessels and to assist the heart in repairing tissue damaged by heart attack and disease. The Greek god of rivers, “Okyanos” symbolizes the primary mechanism of action that these adult stem cells have on ischemic (lack of blood flow) heart tissue, the result of the plaque deposits in the coronary arteries. The stem cells, derived from a person’s adipose (fat) tissue, create new blood vessels, a process known as angiogenesis. These cells facilitate blood flow in the heart and intake and use of oxygen, as measured by a rigorous clinical trial known as the PRECISE trial, as well as cardiac cell therapy trials at leading research institutions. For more information, visit http://www.okyanos.com/.
Anjelica Cummings
MMI Public Relations
(919) 233-6600
anjelica@mmipublicrelations.com
http://twitter.com/MMIPR
http://www.mmipublicrelations.com
Contact
Okyanos Heart Institute
Patty Briguglio
919-233-6600
Patty Briguglio
919-233-6600
Contact
Categories